PapersFlow Research Brief
Parathyroid Disorders and Treatments
Research Guide
What is Parathyroid Disorders and Treatments?
Parathyroid disorders and treatments encompass abnormalities in parathyroid hormone (PTH) secretion, such as secondary hyperparathyroidism in chronic kidney disease, managed through interventions targeting mineral metabolism including phosphate control, vitamin D analogs like calcitriol, and therapies modulating PTH effects on bone and vascular health.
Research on parathyroid disorders and treatments includes 91,845 papers focused on the interplay of parathyroid hormone, FGF23, phosphate, and calcification in chronic kidney disease. Disorders like secondary hyperparathyroidism contribute to hyperphosphatemia and cardiovascular risk in hemodialysis patients, as analyzed in large cohorts. Klotho deficiency exacerbates mineral metabolism disruptions, influencing PTH regulation and vascular calcification.
Topic Hierarchy
Research Sub-Topics
FGF23 in Chronic Kidney Disease Mineral Bone Disorder
This sub-topic investigates elevated FGF23 levels, phosphaturic effects, and associations with cardiovascular events in CKD stages 3-5D. Researchers study regulation by iron status and inflammation.
Hyperphosphatemia Management in Dialysis Patients
This sub-topic covers phosphate binder efficacy, dietary interventions, and dialysate adjustments for controlling serum phosphorus. Researchers compare iron-based versus calcium-based binders.
Klotho Deficiency in Mineral Metabolism
This sub-topic examines soluble and membrane Klotho's role in FGF23-PTH-vitamin D axis dysregulation in CKD. Researchers explore Klotho as a renoprotective and anti-aging factor.
Secondary Hyperparathyroidism Pathophysiology
This sub-topic analyzes parathyroid hyperplasia mechanisms driven by hypocalcemia, hyperphosphatemia, and vitamin D deficiency. Researchers evaluate calcimimetics and parathyroidectomy outcomes.
Vascular Calcification in CKD
This sub-topic studies medial calcification processes involving phosphate, FGF23, and fetuin-A in CKD arteries. Researchers assess imaging biomarkers and inhibitors like SNF472.
Why It Matters
Parathyroid disorders drive morbidity and mortality in maintenance hemodialysis patients through mineral metabolism abnormalities like hyperphosphatemia, hypercalcemia, and secondary hyperparathyroidism. Block et al. (2004) in "Mineral Metabolism, Mortality, and Morbidity in Maintenance Hemodialysis" examined data from 40,538 patients, finding that each 1.0 mg/dL increase in serum phosphate associated with 9% higher mortality risk, while calcium-phosphate product above 72 mg²/dL² linked to 17% increased risk. Treatments such as parathyroid hormone (1-34) reduce vertebral fracture risk by 65% and nonvertebral fracture risk by 53% in postmenopausal women with osteoporosis, as shown by Neer et al. (2001) in "Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis." These findings guide phosphate binders, calcitriol, and PTH analogs in nephrology to mitigate cardiovascular events and bone loss in chronic kidney disease.
Reading Guide
Where to Start
"Mineral Metabolism, Mortality, and Morbidity in Maintenance Hemodialysis" by Block et al. (2004), as it provides foundational data on 40,538 hemodialysis patients linking parathyroid-related mineral disorders to mortality risks, offering direct clinical relevance for understanding treatment needs.
Key Papers Explained
Block et al. (2004) in "Mineral Metabolism, Mortality, and Morbidity in Maintenance Hemodialysis" establishes associations between secondary hyperparathyroidism, hyperphosphatemia, and mortality in 40,538 dialysis patients. Neer et al. (2001) in "Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis" demonstrates PTH (1-34) efficacy in reducing fractures by 65% vertebral and 53% nonvertebral. Brown et al. (1993) in "Cloning and characterization of an extracellular Ca2+-sensing receptor from bovine parathyroid" identifies the receptor regulating PTH secretion, while Almilaji et al. (2014) in "Regulation of the Voltage Gated K+ Channel Kv1.3 by Recombinant Human Klotho Protein" connects Klotho to mineral metabolism modulation.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Current research emphasizes FGF23, Klotho, and phosphate interactions in chronic kidney disease vascular calcification, as reflected in the 91,845 papers. No recent preprints or news available, so frontiers involve expanding Block et al. (2004) associations to personalized PTH and phosphate management in nephrology.
Papers at a Glance
Frequently Asked Questions
What role does secondary hyperparathyroidism play in hemodialysis patients?
Secondary hyperparathyroidism in maintenance hemodialysis patients arises from disorders of mineral metabolism including hyperphosphatemia and hypercalcemia. Block et al. (2004) in "Mineral Metabolism, Mortality, and Morbidity in Maintenance Hemodialysis" reported associations with higher mortality, such as 9% increased risk per 1.0 mg/dL serum phosphate rise. Interventions target these imbalances to reduce cardiovascular morbidity.
How does parathyroid hormone (1-34) treat osteoporosis?
Parathyroid hormone (1-34) at 40 microg daily decreases vertebral fracture risk by 65% and nonvertebral fracture risk by 53% in postmenopausal women with osteoporosis. Neer et al. (2001) in "Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis" showed it increases vertebral, femoral, and total-body bone mineral density. The treatment is well tolerated with dose-dependent efficacy.
What is the function of the extracellular Ca2+-sensing receptor in parathyroid?
The extracellular Ca2+-sensing receptor from bovine parathyroid regulates PTH secretion in response to serum calcium levels. Brown et al. (1993) in "Cloning and characterization of an extracellular Ca2+-sensing receptor from bovine parathyroid" cloned and characterized this receptor. It maintains mineral homeostasis by sensing calcium and modulating parathyroid activity.
How does Klotho regulate mineral metabolism?
Klotho negatively regulates 1,25(OH)2D3 formation and mineral metabolism, contributing to phosphate and calcium balance. Almilaji et al. (2014) in "Regulation of the Voltage Gated K+ Channel Kv1.3 by Recombinant Human Klotho Protein" demonstrated Klotho's role in ion channel regulation. Deficiency links to parathyroid hormone dysregulation in chronic kidney disease.
What are the mortality risks from mineral metabolism disorders in dialysis?
In maintenance hemodialysis, hyperphosphatemia, hypercalcemia, and secondary hyperparathyroidism elevate mortality. Block et al. (2004) analyzed 40,538 patients in "Mineral Metabolism, Mortality, and Morbidity in Maintenance Hemodialysis," linking high phosphate to 9% mortality increase per mg/dL. These factors are modifiable through targeted treatments.
Open Research Questions
- ? How do interactions between FGF23, Klotho deficiency, and PTH contribute to vascular calcification in chronic kidney disease?
- ? What are the long-term cardiovascular outcomes of secondary hyperparathyroidism treatments in hemodialysis patients?
- ? How does the Ca2+-sensing receptor modulate PTH secretion under varying phosphate loads?
- ? What mechanisms link hyperphosphatemia to mortality beyond calcium-phosphate product in mineral metabolism disorders?
- ? How does recombinant Klotho influence ion channels and mineral homeostasis in parathyroid disorders?
Recent Trends
The field encompasses 91,845 works on parathyroid hormone, FGF23, phosphate, and calcification in chronic kidney disease, with highly cited papers like Ömer Toprak et al. in "Magnesium Replacement Improves the Metabolic Profile in Obese and Pre-Diabetic Patients with Mild-to-Moderate Chronic Kidney Disease: A 3-Month, Randomised, Double-Blind, Placebo-Controlled Study" (29,675 citations) highlighting adjunct therapies.
2017Growth data over 5 years unavailable.
No recent preprints or news reported.
Research Parathyroid Disorders and Treatments with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Parathyroid Disorders and Treatments with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers